[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Pengfei Qiu\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100613676","phase-3-rasolve-125i-radioactive-seed-marking-effects-on-pathological-complete-response-rate-and-prognosis-post-neoadjuvant-therapy-in-earlyadvanced-breast-cancer-100613676",false,"NCT07269691","RaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early\u002FAdvanced Breast Cancer","RaSOLVE: An Open-Label, Controlled, Randomized, Multicenter Phase III Clinical Trial Assessing the Impact of Preoperative 125I Radioactive Seed Localization on Pathological Complete Response Rate (tpCR: ypT0\u002Fis ypN0) and Long-Term Prognosis (iDFS\u002FOS) in Women With Early or Locally Advanced Newly Diagnosed Untreated Breast Cancer Following Neoadjuvant Therapy","Inclusion Criteria:\n\n* Female patients aged 18 to 70 years.\n* ECOG performance status 0-1.\n* Pathologically confirmed, previously untreated, unilateral primary invasive breast cancer.\n* Clinical stage cT1cN1-2M0 or cT2-3N0-2M0 (AJCC 8th edition).\n* Adequate organ function within 7 days prior to randomization:\n\n  * Hemoglobin ≥ 90 g\u002FL\n  * ANC ≥ 1.5×10⁹\u002FL; Lymphocyte count ≥ 0.5×10⁹\u002FL\n  * Platelet count ≥ 100×10⁹\u002FL\n  * WBC 3.0-15×10⁹\u002FL\n  * ALT, AST ≤ 2.5×ULN; ALP ≤ 2.5×ULN; TBIL ≤ 1.5×ULN\n  * Serum creatinine ≤ 1.5×ULN and creatinine clearance ≥ 60 mL\u002Fmin\n  * PT, APTT ≤ 1.5×ULN\n  * Urine protein \\\u003C 2+ or 24-hour urine protein ≤ 1 g\n  * LVEF ≥ 55%\n  * QTcF \\\u003C 470 ms\n* Negative serum pregnancy test within 3 days prior to first treatment for women of childbearing potential and agreement to use effective contraception.\n* Willing and able to sign informed consent.\n\nExclusion Criteria:\n\n* Bilateral breast cancer or history of DCIS, LCIS, invasive breast cancer, or metastatic breast cancer.\n* Any malignancy diagnosed within the past 5 years except cured cervical carcinoma in situ or non-melanoma skin cancer.\n* Prior systemic chemotherapy, targeted therapy, immunotherapy, or radiotherapy within 1 year.\n* Prior exposure to anthracyclines, taxanes, or platinum agents.\n* Primary or secondary immunodeficiency; uncontrolled autoimmune disease (except controlled hypothyroidism or type 1 diabetes).\n* Interstitial lung disease or severe chronic lung disease.\n* Clinically significant cardiovascular disease, including:\n\n  * NYHA class ≥ III\n  * Myocardial infarction or stroke within 3 months\n  * Uncontrolled hypertension\n  * Clinically significant arrhythmia or heart failure\n* Arterial\u002Fvenous thrombosis within 3 months.\n* Vaccination with live attenuated vaccine within 28 days.\n* Active HBV, HCV, or HIV infection.\n* Major surgery within 28 days (except diagnostic procedures).\n* Severe infection within 4 weeks or systemic antibiotic-treated infection within 2 weeks.\n* History of bone marrow or organ transplantation.\n* Coagulation abnormalities (INR \\> 1.5 or APTT \\> 1.5×ULN).\n* Peripheral neuropathy ≥ Grade 2.\n* Treatment with systemic immunostimulatory agents within 4 weeks or immunosuppressive agents within 2 weeks.\n* Known allergy to study agents.\n* Participation in another clinical trial within 4 weeks.\n* Pregnancy, breastfeeding, or planning pregnancy.\n* Substance abuse or psychiatric conditions that may affect compliance.\n* Any condition that, in the investigator's judgment, makes the patient unsuitable for the study.","FEMALE","18 Years","70 Years",{"count":20,"type":21},194,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study is an open-label, controlled, multicenter phase III clinical trial designed to evaluate whether the use of iodine-125 radioactive seed markers can improve treatment response for patients with early or locally advanced breast cancer undergoing neoadjuvant therapy.\n\nNeoadjuvant therapy is widely used for breast cancer to shrink tumors, increase the chances of breast-conserving surgery, and help determine the most effective postoperative treatments. Achieving a pathological complete response (pCR) after neoadjuvant therapy is strongly associated with better long-term outcomes.\n\nIn this study, qualified participants will be randomly assigned in a 1:1 ratio to either the experimental group or the control group.\n\nExperimental group: Patients will receive placement of iodine-125 seed markers in the primary breast tumor and biopsy-proven positive axillary lymph nodes before starting neoadjuvant therapy.\n\nControl group: Patients will undergo standard neoadjuvant therapy without seed placement.\n\nAll participants will then complete neoadjuvant therapy followed by surgery. Pathological evaluation will determine whether the cancer has completely disappeared. Long-term outcomes, including invasive disease-free survival, will be followed for at least five years.\n\nThe goal of this study is to determine whether radioactive seed marking can increase the rate of pathological complete response and improve prognosis in patients receiving neoadjuvant therapy for breast cancer. The study will also explore whether iodine-125 seeds may activate immune responses that contribute to treatment effectiveness.",[27,28],"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","Breast Cancer",[30],"Iodine-125 seed Radioactive seed marking Breast cancer Neoadjuvant therapy Pathological complete response","NOT_YET_RECRUITING","2025-11-26",{"date":34,"type":35},"2025-12-08","ACTUAL",{"date":37,"type":21},"2025-12-01",{"date":39,"type":21},"2027-12-01",{"name":41,"class":42},"Pengfei Qiu","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":43},"100584509","the-treatment-of-moderate-to-severe-allergic-rhinitis-with-electroacupuncture-combined-with-microneedle-knife-100584509","NCT06890260","The Treatment of Moderate to Severe Allergic Rhinitis With Electroacupuncture Combined With Microneedle Knife","A Clinical Randomized Controlled Study of Electroacupuncture Combined With Microneedle Knife in the Treatment of Moderate to Severe Allergic Rhinitis","Inclusion Criteria:\n\n1. Those with clinical and laboratory diagnosis of moderate to severe allergic rhinitis;\n2. Aged ≥18 years and ≤75 years, with no restriction on gender or ethnicity;\n3. Not taking drugs such as antihistamines or nasal steroids within 1 month before enrollment;\n4. Those who voluntarily participated in this study and signed an informed consent form, and who were able to adhere to outpatient treatment for 4 weeks.\n\nExclusion Criteria:\n\n1. Atrophic rhinitis, hypertrophic rhinitis, vasomotor rhinitis, acute and chronic sinusitis, nasal polyps, severe septal deviation, eosinophilia non-allergic rhinitis;\n2. Those with other allergic diseases such as asthma, urticaria, and colds that cause nasal congestion, runny nose, and sneezing;\n3. Those who have serious diseases such as cardiovascular, cerebrovascular, hepatic, renal and hematopoietic systems in combination;\n4. Pregnant or lactating women, psychiatric patients, patients with malignant tumors.","ALL","75 Years",{"count":54,"type":21},90,[56],"NA","Based on the inclusion and exclusion criteria, patients with allergic rhinitis who meet the requirements are selected as trial subjects, and the efficacy is clarified in a randomized controlled design trial. We will Use the total nasal symptom score as the primary outcome index, serum chemokine, intercellular adhesion molecule-1, eosinophil cationic protein, total non-nasal symptom score, and rhinitis-related quality of life scale as secondary outcome indexes, and oral cetirizine hydrochloride tablets and nasal budesonide spray as the control group, the efficacy of the subjects in the electroacupuncture combined with microneedle knife group and the drug group will be observed respectively before treatment, after 2 weeks of treatment, after 4 weeks, 1 month follow-up after the end of treatment, and 3 months follow-up after the end of treatment. 4 weeks later, 1 month follow-up after the end of treatment and 3 months follow-up after the end of treatment.",[59,60,61],"Allergic Rhinitis (Disorder)","Electroacupuncture","Microneedle Knife","RECRUITING","2025-03-27",{"date":65,"type":35},"2025-03-30",{"date":67,"type":21},"2025-04-11",{"date":69,"type":21},"2027-12-31",{"name":41,"class":42},""]